World's first hydroxychloroquine treatment of new coronary pneumonia multi-center clinical results released: ineffective

REVIEW: China Ruijin Hospital published trials, a number of European and American studies were negativeNational multi-centerby the Shanghai Jiaotong University School of Medicine Affiliated Ruijin Hospital (hereinafter referred to Ruijin Hospital) led the country designated 16 new patients admitted with pneumonia crown research sub-centers participating, parallel, randomized controlled clinical study - hydroxychloroquine sulfate treatment of pneumonia crown new research results recently published in the "British Medical Journal." The results showed that, compared with standard therapy, therapy combined with hydroxychloroquine can not bring additional benefit of virus was negative, and there is a certain probability of occurrence of gastrointestinal symptoms to adverse events that test results do not support light The new crown patients with moderate pneumonia in combination with hydroxychloroquine for treatmenthydroxychloroquine as an anti-malarial drugs and anti-inflammatory drugs, and has been in the Department of Infectious Diseases, Division of Rheumatology for many years, but there is no clinical studies verify the efficacy of its new crown in the treatment of pneumonia, the lack of safety dataThe clinical study of Ruijin Hospital led, high doses of hydroxychloroquine explore new crown pneumonia efficacy and safety in patients with pneumonia nucleic new crown diagnosed inAccording to reports, this study enrolled a total of 150 hospitalized patients infected with a nucleic acid-positive crown new virus were divided randomly into hydroxychloroquine combination with standard treatment group (75 cases) and the standard treatment group (75 cases), the standard treatment group to give a new crown viral Directory infection recommended standard treatment, hydroxychloroquine combination with standard treatment group administering high doses of hydroxychloroquine (1 to 3 days based on the standard treatment, hydroxychloroquine sulfate 1200 mg / day, subsequent 800 mg / day , patients with mild to moderate course of 14 days, the treatment of critically ill patients 21 days) ofPatients participating in the study are at the critical stage, the average time starts from hydroxychloroquine to the diseased group was 16.6 daysnucleic negative rate of 28 days no significant difference in combined standard treatment with hydroxychloroquine and standard treatment group was 85.4% (95% CI 73.8% to 93.8%) and 81.3% (95% CI 71.2 % to 89.6%)Safety, adverse events occurred standard therapy group was 8.8%, while hydroxychloroquine combined standard treatment group was 30%Hydroxychloroquine most common adverse reactions associated diarrhea (10% incidence rate)But both groups no serious treatment-related adverse eventsexperts said the study is a clinical study of hydroxychloroquine the world's first multi-center randomized controlled treatment of mild to moderate pneumonia new crown, providing the most realistic and precise basis for the clinical positioning of hydroxychloroquine in the treatment of pneumonia new crownpapers related information:http://dx.doi.org/10.1136/bmj.m1849Editor: Meng MengRelated Tags :a global, hydroxychloroquine , a new crown virus, clinical trials 0 0